Skip to content

Treatment of patients with functional neurological symptoms: a randomized controlled trial

Treatment of patients with functional neurological symptoms: a randomized controlled trial - Treatment of functional neurological symptoms

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON32277
Enrollment
200
Registered
2008-07-15
Start date
2008-06-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medically unexplained symptoms unexplained physical symptoms

Interventions

After information on the diagnosis, baseline assessment and randomisation, patients will receive either standard treatment by their GP*s (control group) or educational treatment by a neurologist (in

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients (>18 years old) with neurological physical symptoms unexplained by disease. The following clusters of symptoms will be included: * Tension type headache * Back and neck pain * Pseudo movement disorders * Mainly sensory disturbances * Mainly motor disturbances * Pseudo-epilepsy

Exclusion criteria

Exclusion criteria: * Duration of symptoms more than one year * Patients known prior to assessment to have psychiatric disorders other than somatoform, depressive, or anxiety disorders * Patients with a primary diagnosis of a severe mood, anxiety, or psychotic disorders requiring psychiatric treatment * Patients who are in dispute about financial or social benefit * Patients suffering from a major somatic disease, incl neurological disease

Design outcomes

Primary

MeasureTime frame
The primary outcome is the patient*s level of activities of daily living 12 months after Randomisation. Physical disability will be assessed with the AMC linear disability scale (ALDS).

Secondary

MeasureTime frame
Secondary outcomes are the 'hospital anxiety and depression scale' (HADS), symptom score, work/leisure activities, absence of work, medical consumption and quality of life (SF-36).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)